FY2018 Revenue Forecast for TESARO Inc Issued By SunTrust Banks (TSRO)

FY2018 Revenue Forecast for TESARO Inc Issued By SunTrust Banks (TSRO)

TESARO Inc (NASDAQ:TSRO) – SunTrust Banks lifted their FY2018 earnings estimates for TESARO in a note issued to investors on Monday. SunTrust Banks analyst P. Lawson now forecasts that the firm will post earnings per share of ($3.06) for the year, up from their prior estimate of ($3.97). SunTrust Banks currently has a “Average” rating and a $190.00 target price on the stock.

TSRO has been the subject of several other research reports. Citigroup Inc restated a “sell” rating and set a $238.00 price target on shares of TESARO in a research note on Monday, January 30th. Cowen and Company started coverage on shares of TESARO in a research note on Monday, February 6th. They set a “market perform” rating and a $155.00 price target for the company. Zacks Investment Research lowered shares of TESARO from a “hold” rating to a “sell” rating in a research note on Wednesday, March 22nd. Leerink Swann restated a “market perform” rating on shares of TESARO in a research note on Monday, March 20th. Finally, Credit Suisse Group AG set a $151.00 price target on shares of TESARO and gave the stock a “buy” rating in a research note on Thursday, January 12th. Six equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $167.37.

Shares of TESARO (NASDAQ:TSRO) opened at 153.87 on Thursday. The firm’s 50-day moving average price is $170.49 and its 200 day moving average price is $140.21. TESARO has a 1-year low of $36.68 and a 1-year high of $192.94. The company’s market capitalization is $8.25 billion.

In related news, VP Edward C. English sold 10,000 shares of TESARO stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $178.06, for a total value of $1,780,600.00. Following the completion of the transaction, the vice president now directly owns 5,396 shares in the company, valued at approximately $960,811.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Edward C. English sold 229 shares of TESARO stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $177.61, for a total transaction of $40,672.69. Following the completion of the transaction, the vice president now owns 625 shares of the company’s stock, valued at $111,006.25. The disclosure for this sale can be found here. Insiders sold a total of 15,793 shares of company stock valued at $2,801,638 over the last quarter. 40.50% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TSRO. Macquarie Group Ltd. raised its position in TESARO by 4.8% in the fourth quarter. Macquarie Group Ltd. now owns 301,510 shares of the biopharmaceutical company’s stock worth $40,547,000 after buying an additional 13,830 shares in the last quarter. Opus Point Partners Management LLC acquired a new position in TESARO during the fourth quarter worth $1,345,000. Teachers Advisors LLC raised its position in TESARO by 177.0% in the fourth quarter. Teachers Advisors LLC now owns 126,357 shares of the biopharmaceutical company’s stock worth $16,992,000 after buying an additional 80,744 shares in the last quarter. Norges Bank acquired a new position in TESARO during the fourth quarter worth $40,158,000. Finally, Putnam Investments LLC raised its position in TESARO by 0.4% in the fourth quarter. Putnam Investments LLC now owns 10,429 shares of the biopharmaceutical company’s stock worth $1,402,000 after buying an additional 46 shares in the last quarter. Institutional investors and hedge funds own 98.48% of the company’s stock.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Related posts

Leave a Comment